APA (7th ed.) Citation

S, V., N, D., NJ, S., D, E., Q, Z., L, Y., . . . M, d. L. (2026). Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22. Research square. https://doi.org/10.21203/rs.3.rs-8605291/v1

Chicago Style (17th ed.) Citation

S, Vasu, et al. "Safety and Clinical Outcomes of a First-in-human Trial of Point-of-care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22." Research Square 2026. https://doi.org/10.21203/rs.3.rs-8605291/v1.

MLA (9th ed.) Citation

S, Vasu, et al. "Safety and Clinical Outcomes of a First-in-human Trial of Point-of-care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22." Research Square, 2026, https://doi.org/10.21203/rs.3.rs-8605291/v1.